Coverage
-
July 29, 2016
A D.C. federal judge on Thursday rejected Otsuka Pharmaceutical's effort to derail a rival version of schizophrenia drug Abilify Maintena, calling its logic "convoluted" and obviously aimed at perpetually thwarting competition.
2 other articles on this case.
View all »